VJHemOnc is committed to improving our service to you

EHA 2015 | Integrating novel agents into the treatment of multiple myeloma

VJHemOnc is committed to improving our service to you

Pieter Sonneveld

There is now a rich pipeline of novel agents in clinical trials for the treatment of patients with multiple myeloma. At the 20th Congress of the European Hematology Association (EHA), Pieter Sonneveld, MD, of the Erasmus MC University Cancer Institute, Rotterdam, the Netherlands, discusses the impact of these novel agents in current treatment practices for multiple myeloma.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter